Literature DB >> 26174839

Should procalcitonin be measured routinely in acute decompensated heart failure?

Goran Loncar1, Verena Tscholl2,3, Elvis Tahirovic2, Nikola Sekularac1, Almuth Marx4, Danilo Obradovic2, Jovan Veskovic2, Mitja Lainscak5,6, Stephan von Haehling7,8, Frank Edelmann2, Aleksandra Arandjelovic1,9, Svetlana Apostolovic10, Dragana Stanojevic10, Burkert Pieske2, Tobias Trippel2, Hans-Dirk Dungen2.   

Abstract

AIM: To elucidate the prognostic role of procalcitonin (PCT) in patients with acute decompensated heart failure (ADHF) without clinical signs of infection at admission. MATERIALS &
METHODS: Serial measurements of PCT and NT-proBNP were performed in 168 patients, aged 68 ± 10 years with ADHF followed by 3-month outcome evaluation.
RESULTS: Cox regression analysis demonstrated significant predictive value of baseline PCT for all-cause death/hospitalization (area under the curve: 0.67; p = 0.013) at 90th day. The patients with persistently elevated PCT or with an increase during the first 72 h of hospitalization had the worst prognosis (p = 0.0002).
CONCLUSION: Baseline and serial in-hospital measurements of PCT have significant prognostic properties for 3-month all-cause mortality/hospitalization in patients with ADHF without clinical signs of infection at admission.

Entities:  

Keywords:  ADHF; NT-proBNP; procalcitonin; prognosis; serial measurements

Mesh:

Substances:

Year:  2015        PMID: 26174839     DOI: 10.2217/bmm.15.29

Source DB:  PubMed          Journal:  Biomark Med        ISSN: 1752-0363            Impact factor:   2.851


  4 in total

Review 1.  The Confounding Effects of Non-cardiac Pathologies on the Interpretation of Cardiac Biomarkers.

Authors:  Marin Nishimura; Alison Brann; Kay-Won Chang; Alan S Maisel
Journal:  Curr Heart Fail Rep       Date:  2018-08

Review 2.  The role of procalcitonin in acute heart failure patients.

Authors:  Martin Möckel; Julia Searle; Alan Maisel
Journal:  ESC Heart Fail       Date:  2017-07-18

Review 3.  Beyond the Limits: Clinical Utility of Novel Cardiac Biomarkers.

Authors:  Radmilo Janković; Danica Marković; Nenad Savić; Vesna Dinić
Journal:  Biomed Res Int       Date:  2015-10-04       Impact factor: 3.411

4.  Procalcitonin (PCT) Predicts Worse Outcome in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF).

Authors:  J Banach; Ł Wołowiec; D Rogowicz; L Gackowska; I Kubiszewska; W Gilewski; J Michałkiewicz; W Sinkiewicz
Journal:  Dis Markers       Date:  2018-08-28       Impact factor: 3.434

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.